About Dr. Michael Roth
Dr. Michael Roth graduated from New York University School of Medicine and completed a Pediatrics residency and Pediatric Hematology/Oncology fellowship at the Albert Einstein College of Medicine. He is currently an associate professor of pediatrics at The University of Texas MD Anderson Cancer Center. Dr. Roth specializes in caring for children and adolescents with leukemia and lymphoma and he is the Director of the Childhood Cancer Survivorship Program. Dr. Roth’s clinical research focuses on improving outcomes for adolescents and young adults (AYA) with cancer and he is the associate vice chair for clinical trials and therapeutics in the Children’s Oncology Group AYA Oncology Discipline Committee. In addition, Dr. Roth is the co-director of the AYA Program at The University of Texas MD Anderson Cancer Center.
Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Director, Adolescent and Young Adult (AYA) Oncology Program, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Childhood Cancer Survivorship Program, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
|2006||New York University School of Medicine, New York, NY, USA, MD, Medicine|
|2002||Brandeis University, Waltham, MA, USA, BA, Biology|
|2010-2012||Research Fellowship, Laboratory of Cell Biology, Albert Einstein College of Medicine, Bronx, NY|
|2009-2012||Clinical Fellowship, Pediatrics Hematology/Oncology, Albert Einstein College of Medicine, Children’s Hospital at Montefiore, Bronx, NY|
|2006-2009||Intern & Resident, Pediatrics, Albert Einstein College of Medicine, Bronx, NY|
|2013||American Board of Pediatrics, Pediatric Hematology-Oncology|
|2009||American Board of Pediatrics, General Pediatrics|
Institutional Committee Activities
Chair, Pediatric Hematology/Oncology Program Evaluation Committee, Children’s Cancer Hospital, 2017 - Present
|2017||New York Super Doctors- Best Doctors|
|2013||New York Super Doctors Rising Stars|
- Zhu C, Olson KA, Roth M, Geller DS, Gorlick RG, Gill J, Laack NN, Randall RL. Provider views on the management of Ewing sarcoma of the spine and pelvis. J Surg Oncol 117(3):417-424, 2018. e-Pub 2017. PMID: 29044582.
- Maxwell RR, Egan-Sherry D, Gill JB, Roth ME. Management of Chemotherapy-Induced Febrile Neutropenia in Pediatric Oncology Patients: A North American Survey of Pediatric Hematology/Oncology and Pediatric Infectious Disease Physicians. Pediatr Blood Cancer 64(12), 2017. e-Pub 2017. PMID: 28748605.
- Ren T, Piperdi S, Koirala P, Park A, Zhang W, Ivenitsky D, Zhang Y, Villanueva-Siles E, Hawkins DS, Roth M, Gorlick R. CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. Oncotarget 8(50):87848-87859, 2017. e-Pub 2017. PMID: 29152125.
- Morris J, Yang R, Roth M, Gill J, Gorlick R, Lo Y, Hoang BH, Garfein E, Geller DS. Mechanical analysis of the vascularized fibular graft prosthetic composite (VFGPC) for internal hemipelvectomy reconstruction. J Surg Oncol 115(7):864-869, 2017. e-Pub 2017. PMID: 28543392.
- Gill J, Connolly P, Roth M, Chung SH, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Morris J, Gorlick R, Geller DS. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. PLoS One 12(3):e0173322, 2017. e-Pub 2017. PMID: 28264040.
- Yang Y, Yang R, Roth M, Piperdi S, Zhang W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, Zhang Y, Sowers R, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. Genes Cancer 8(1-2):484-494, 2017. PMID: 28435520.